Praxis Precision Medicines Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
PRAX$332.97+19.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $215,372 | $81,300 |
| Marketable securities | 177,195 | — |
| Prepaid expenses and other current assets | 11,805 | 3,580 |
| Total current assets | 404,372 | 84,880 |
| Long-term marketable securities | 76,961 | — |
| Property and equipment, net | 230 | 588 |
| Operating lease right-of-use assets | 1,131 | 2,064 |
| Other non-current assets | 416 | 416 |
| Total assets | $483,110 | $87,948 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $12,528 | $5,815 |
| Accrued expenses | 23,763 | 7,416 |
| Operating lease liabilities | 1,259 | 1,126 |
| Current portion of deferred revenue | — | 1,392 |
| Total current liabilities | 37,550 | 15,749 |
| Long-term liabilities: | ||
| Non-current portion of operating lease liabilities | 110 | 1,369 |
| Non-current portion of deferred revenue | — | 1,161 |
| Total liabilities | 37,660 | 18,279 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 150,000,000 shares authorized; 19,422,358 shares issued and outstanding as of December 31, 2024, and 8,791,877 shares issued and outstanding as of December 31, 2023 | 14 | 13 |
| Additional paid-in capital | 1,281,522 | 723,577 |
| Accumulated other comprehensive gain | 654 | — |
| Accumulated deficit | (836,740) | (653,921) |
| Total stockholders’ equity | 445,450 | 69,669 |
| Total liabilities and stockholders’ equity | $483,110 | $87,948 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.